Therapy Areas: Oncology
K36 Therapeutics completes first patient cohort dosing for Phase 1 trial of KTX-2001
6 February 2026 - Clinical-stage biotechnology company K36 Therapeutics Inc on Thursday announced completion of dosing in the first patient cohort of its Phase 1 clinical trial evaluating KTX-2001, a ...
Partner Therapeutics' zenocutuzumab-zbco granted US FDA Orphan Drug Designation for treatment of cholangiocarcinoma
6 February 2026 - Biotechnology company Partner Therapeutics Inc (PTx) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zenocutuzumab-z...
Hologic receives FDA approval for Aptima HPV assay as primary screening option
4 February 2026 - Women's health company Hologic Inc (Nasdaq:HOLX) announced on Wednesday that the US Food and Drug Administration (FDA) has approved its Aptima HPV Assay for clinician-collected ...
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
4 February 2026 - Cizzle Biotechnology Holdings plc (LSE: CIZ), a UK-based developer of diagnostic tests for early-stage cancer, announce on Wednesday that it has been granted patent protection in Can...
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082
4 February 2026 - Biosion Inc, a China-based clinical-stage biotechnology company developing innovative antibody-based therapeutics, announced on Tuesday that the first patient has been dosed in a Pha...
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
3 February 2026 - US-based clinical-stage precision medicine company Relay Therapeutics, Inc. (NASDAQ: RLAY) on Tuesday said the US Food and Drug Administration has granted Breakthrough Therapy design...